Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AP4O
|
|||
| Former ID |
DPR000123
|
|||
| Drug Name |
Gem 92
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Discontinued in Phase 1 | [1] | |
| Therapeutic Class |
Antisense
|
|||
| Company |
Idera Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus GAG protein (HIV gag) | Target Info | Modulator | [2] |
| Reactome | Uncoating of the HIV Virion | |||
| Budding and maturation of HIV virion | ||||
| Integration of provirus | ||||
| Early Phase of HIV Life Cycle | ||||
| Minus-strand DNA synthesis | ||||
| Plus-strand DNA synthesis | ||||
| 2-LTR circle formation | ||||
| Binding and entry of HIV virion | ||||
| Membrane binding and targetting of GAG proteins | ||||
| Assembly Of The HIV Virion | ||||
| Integration of viral DNA into host genomic DNA | ||||
| Autointegration results in viral DNA circles | ||||
| APOBEC3G mediated resistance to HIV-1 infection | ||||
| Vpr-mediated nuclear import of PICs | ||||
| WikiPathways | Host Interactions of HIV factors | |||
| HIV Life Cycle | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008217) | |||
| REF 2 | Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.